Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Am J Physiol Lung Cell Mol Physiol ; 301(4): L427-40, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21784970

ABSTRACT

Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) is a homeodomain-containing transcription factor essential for the morphogenesis and differentiation of the lung. In the lung, TTF-1 controls the expression of surfactant proteins that are essential for lung stability and lung host defense. In this study, we identified functionally important transcription factor binding sites in the TTF-1 proximal promoter and studied tumor necrosis factor-α (TNF-α) regulation of TTF-1 expression. TNF-α, a proinflammatory cytokine, has been implicated in the pathogenesis of acute respiratory distress syndrome (ARDS) and inhibits surfactant protein levels. Deletion analysis of TTF-1 5'-flanking DNA indicated that the TTF-1 proximal promoter retained high-level activity. Electrophoretic mobility shift assay, chromatin immunoprecipitation, and mutational analysis experiments identified functional ZBP-89, Sp1, Sp3, and TTF-1 sites in the TTF-1 proximal promoter. TNF-α inhibited TTF-1 protein levels in H441 and primary alveolar type II cells. TNF-α inhibited TTF-1 gene transcription and promoter activity, indicating that transcriptional mechanisms play important roles in the inhibition of TTF-1 levels. TNF-α inhibited TTF-1 but not Sp1 or hepatocyte nuclear factor-3 DNA binding to TTF-1 promoter. Transactivation experiments in A549 cells indicated that TNF-α inhibited TTF-1 promoter activation by exogenous Sp1 and TTF-1 without altering their levels, suggesting inhibition of transcriptional activities of these proteins. TNF-α inhibition of TTF-1 expression was associated with increased threonine, but not serine, phosphorylation of Sp1. Because TTF-1 serves as a positive regulator for surfactant protein gene expression, TNF-α inhibition of TTF-1 expression could have important implications for the reduction of surfactant protein levels in diseases such as ARDS.


Subject(s)
DNA-Binding Proteins/metabolism , Epithelial Cells/metabolism , Lung/metabolism , Nuclear Proteins , Promoter Regions, Genetic , Respiratory Distress Syndrome/metabolism , Sp1 Transcription Factor/metabolism , Sp3 Transcription Factor/metabolism , Transcription Factors/metabolism , Transcriptional Activation , Tumor Necrosis Factor-alpha/pharmacology , Base Sequence , Cell Line, Tumor , Cell Survival/drug effects , DNA-Binding Proteins/genetics , Epithelial Cells/pathology , Humans , Lung/pathology , Molecular Sequence Data , Mutation , Nuclear Proteins/chemistry , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Phosphorylation , Plasmids , Protein Binding , Respiratory Distress Syndrome/genetics , Respiratory Distress Syndrome/pathology , Reverse Transcriptase Polymerase Chain Reaction , Sp1 Transcription Factor/genetics , Sp3 Transcription Factor/genetics , Thyroid Nuclear Factor 1 , Transcription Factors/chemistry , Transcription Factors/genetics , Transfection
2.
Am J Physiol Lung Cell Mol Physiol ; 299(2): L252-62, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20418387

ABSTRACT

Surfactant protein B (SP-B) is essential for the surface tension-lowering function of pulmonary surfactant. Surfactant dysfunction and reduced SP-B levels are associated with elevated nitric oxide (NO) in inflammatory lung diseases, such as acute respiratory distress syndrome. We previously found that NO donors decreased SP-B expression in H441 and MLE-12 lung epithelial cells by reducing SP-B promoter activity. In this study, we determined the roles of DNA elements and interacting transcription factors necessary for NO inhibition of SP-B promoter activity in H441 cells. We found that the NO donor diethylenetriamine-nitric oxide adduct (DETA-NO) decreased SP-B promoter thyroid transcription factor 1 (TTF-1), hepatocyte nuclear factor 3 (HNF-3), and Sp1 binding activities but increased activator protein 1 (AP-1) binding activity. DETA-NO decreased TTF-1, but not Sp1, levels, suggesting that reduced TTF-1 expression contributes to reduced TTF-1 binding activity. Lack of effect on Sp1 levels suggested that DETA-NO inhibits Sp1 binding activity per se. Overexpression of Sp1, but not TTF-1, blocked DETA-NO inhibition of SP-B promoter activity. DETA-NO inhibited SP-B promoter induction by exogenous TTF-1 without altering TTF-1 levels. DETA-NO decreased TTF-1 mRNA levels and gene transcription rate, indicating that DETA-NO inhibits TTF-1 expression at the transcriptional level. We conclude that NO inhibits SP-B promoter by decreasing TTF-1, Sp1, and HNF-3 binding activities and increasing AP-1 binding activity. NO inhibits TTF-1 levels and activity to decrease SP-B expression. NO inhibition of SP-B expression could be a mechanism by which surfactant dysfunction occurs in inflammatory lung diseases.


Subject(s)
Nitric Oxide/pharmacology , Pulmonary Surfactant-Associated Protein B/biosynthesis , Respiratory Mucosa/metabolism , Transcription Factors/physiology , Cell Line , Forkhead Transcription Factors/genetics , Gene Deletion , Gene Expression Regulation/drug effects , Humans , Promoter Regions, Genetic/drug effects , Pulmonary Surfactant-Associated Protein B/genetics , Respiratory Mucosa/drug effects , Sp1 Transcription Factor/genetics , Transcription Factor AP-1/genetics , Transcription Factors/genetics , Triazenes/pharmacology
3.
Gene ; 391(1-2): 150-60, 2007 Apr 15.
Article in English | MEDLINE | ID: mdl-17306937

ABSTRACT

Tumor necrosis factor-alpha (TNF-alpha) is an important cytokine involved in the pathogenesis of inflammatory diseases of the lung. Interleukin-8 (IL-8), a C-X-C chemokine, is induced by TNF-alpha and initiates injury by acting as a chemoattractant for neutrophils and other immune cells. Although sphingolipids such as ceramide and sphingosine 1-phosphate (S1-P) have been shown to serve as signaling molecules in the TNF-alpha inflammatory response, their role in the TNF-alpha induction of IL-8 gene expression in lung epithelial cells is not known. We investigated the role of sphingolipids in the TNF-alpha induction of IL-8 gene expression in H441 lung epithelial cells. We found that TNF-alpha induced IL-8 mRNA levels by increasing gene transcription, and the stability of IL-8 mRNA was not affected. Exogenous S1-P but not ceramide or sphingosine increased IL-8 mRNA levels and IL-8 secretion. Dimethylsphingosine, an inhibitor of sphingosine kinase, partially inhibited TNF-alpha induction of IL-8 mRNA levels indicating the importance of intracellular increases in S1-P in the IL-8 induction. S1-P induction of IL-8 mRNA was due to an increase in gene transcription, and the stability of IL-8 mRNA was not affected. S1-P induction of IL-8 mRNA was associated with an increase in the binding activity of AP-1 but the activities of NF-kappaB and NF IL-6 were unchanged. S1-P induced the phosphorylation of ERK, p38 and JNK MAPKs. Pharmacological inhibitors of ERK and p38 but not JNK partly inhibited S1-P induction of IL-8 mRNA levels. These data show that increases in the intracellular S1-P partly mediate TNF-alpha induction of IL-8 gene expression in H441 lung epithelial cells via ERK and p38 MAPK signaling pathways and increased AP-1 DNA binding.


Subject(s)
Gene Expression Regulation/drug effects , Interleukin-8/genetics , Lysophospholipids/pharmacology , Sphingosine/analogs & derivatives , Tumor Necrosis Factor-alpha/pharmacology , Blotting, Northern , Cell Line, Tumor , Ceramides/pharmacology , Electrophoretic Mobility Shift Assay , Epithelial Cells/metabolism , Epithelial Cells/pathology , Humans , Immunoblotting , Luciferases/genetics , Luciferases/metabolism , Lung/metabolism , Lung/pathology , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Oligonucleotides/metabolism , Protein Binding/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Sphingosine/pharmacology , Time Factors , Transcription Factor AP-1/metabolism , Transcription, Genetic/drug effects , Transfection
4.
Am J Physiol Lung Cell Mol Physiol ; 290(2): L351-8, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16183668

ABSTRACT

Ceramide, a sphingolipid, is an important signaling molecule in the inflammatory response. Mediators of acute lung injury such as TNF-alpha, platelet-activating factor, and Fas/Apo ligand stimulate sphingomyelin hydrolysis to increase intracellular ceramide levels. Surfactant protein B (SP-B), a hydrophobic protein of pulmonary surfactant, is essential for surfactant function and lung stability. In this study we investigated the effects of ceramide on SP-B gene expression in H441 lung epithelial cells. Ceramide decreased SP-B mRNA levels in control and dexamethasone-treated cells after 24-h incubation and inhibition of SP-B mRNA was associated with inhibition of immunoreactive SP-B. In transient transfections assays, ceramide inhibited SP-B promoter activity, indicating that the inhibitory effects are exerted at the transcriptional level. Deletion mapping experiments showed that the ceramide-responsive region is located within the -233/-80-bp region of human SP-B promoter. Electrophoretic mobility shift and reporter assays showed that ceramide reduced the DNA binding activity and transactivation capability of thyroid transcription factor 1 (TTF-1/Nkx2.1), a key factor for SP-B promoter activity. Collectively these data showed that ceramide inhibits SP-B gene expression by reducing the DNA biding activity of TTF-1/Nkx2.1 transcription factor. Protein kinase C inhibitor bisindolylmaleimide and the protein tyrosine kinase inhibitor genistein partially reversed ceramide inhibition, indicating that protein kinases play important roles in the ceramide inhibition of SP-B gene expression. Chemical inhibitors of de novo ceramide synthesis and sphingomyelin hydrolysis had no effect on TNF-alpha inhibition of SP-B promoter activity and mRNA levels, suggesting that ceramide does not play a role in the inhibition.


Subject(s)
DNA/metabolism , Nuclear Proteins/metabolism , Pulmonary Surfactant-Associated Protein B/biosynthesis , Sphingosine/analogs & derivatives , Transcription Factors/metabolism , Down-Regulation , Gene Expression Regulation , Hepatocyte Nuclear Factor 3-alpha/drug effects , Humans , Lung Neoplasms , Lysophospholipids/pharmacology , Promoter Regions, Genetic/drug effects , Protein Kinases/physiology , RNA, Messenger/antagonists & inhibitors , Signal Transduction/drug effects , Sphingosine/pharmacology , Sphingosine/physiology , Thyroid Nuclear Factor 1 , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL